The central obstacle in solid tumor CAR T therapy has always been target selection. The therapy works by collecting a patient’s own T cells, genetically engineering them to recognize a specific protein on the surface of cancer cells, and reinfusing them so they hunt down and destroy anything bearing that molecular signature. In blood cancers, this is relatively straightforward because malignant B cells display molecules such as CD19 that are dispensable elsewhere in the body. Solid tumors are different. Most of their defining abnormalities hide inside the cell, driven by mutated or fused genes operating in the nucleus, while the proteins displayed on the cell surface tend to be shared with healthy tissues. Attacking them risks catastrophic off-tumor toxicity, and tumors that do express a target often do so unevenly, allowing antigen-negative cells to survive and seed relapse.

The research team approached this problem from a different angle: instead of searching for surface proteins common to broad cancer types, they looked for surface proteins that are directly commanded into existence by the specific gene fusions that drive certain rare cancers. Alveolar soft-part sarcoma, or ASPS, is a striking example. This aggressive sarcoma, which disproportionately strikes adolescents and young adults, is caused by a chromosome rearrangement that fuses the TFE3 transcription factor gene to the ASPSCR1 gene. Translocation renal cell carcinoma, similarly, arises from fusions involving MiT/TFE-family transcription factors such as TFE3 or TFEB. Because these fusion proteins are aberrant transcription factors, they rewire the cell’s gene expression program wholesale, and the investigators reasoned that this rewiring might force cancer cells to display unique combinations of surface molecules.

Using gene expression profiling across primary and relapsed tumor samples, the team identified glycoprotein NMB, or GPNMB, as a molecule that fits the bill. GPNMB is a transmembrane glycoprotein that in these fusion-driven cancers is expressed at high levels, with striking uniformity across tumor cells and remarkable stability over time. In ASPS and translocation renal cell carcinoma samples, including tumors that had relapsed after prior therapies, essentially every malignant cell carried GPNMB on its surface. This homogeneity is exactly what a CAR T target needs, because it denies tumor cells the escape route of simply switching the target off. Equally important, GPNMB expression in normal tissues is low and restricted, raising the prospect of a workable therapeutic window.

With the target validated, the researchers engineered a CAR T cell product they named GCAR1. The construct couples an antibody-derived recognition domain that binds GPNMB to intracellular signaling modules that activate the T cell upon contact, triggering killing of the target cell and proliferation of the engineered population. In the laboratory, GCAR1 cells showed potent, selective cytotoxicity against patient-derived tumor cells, lysing GPNMB-positive cancer cells while sparing matched normal cells that lacked the protein. The activity extended beyond flat cultures of cells into three-dimensional patient-derived organoids, which better recapitulate the architecture and drug resistance of real tumors, and into xenograft models in which human tumors were implanted in immunodeficient mice. In those animal models, GCAR1 infusions produced marked tumor control, establishing preclinical proof that the approach could work in living tissue.

The pivotal step came with the launch of a first-in-human, open-label, individual-participant clinical trial, registered as NCT07104682, designed to test GCAR1 in patients with relapsed or refractory fusion-driven solid tumors. The study reported here includes an interim analysis of a participant with metastatic ASPS whose disease had progressed despite standard treatment. Following lymphodepleting chemotherapy to clear space for the engineered cells, the patient received a single infusion of GCAR1. The clinical response, while not a complete remission, was notable: imaging showed stable disease sustained for up to three months, and, strikingly, many of the patient’s non-target lesions, smaller metastatic deposits not formally measured as primary endpoints, resolved entirely on follow-up scans. In a cancer as relentless as ASPS, with few effective systemic options and a median survival historically measured in a few years from diagnosis, even disease stabilization with lesion regression represents a meaningful clinical signal.

Just as important as the efficacy signal was the safety profile. GCAR1 was well tolerated, without the severe cytokine release syndrome, neurotoxicity, or on-target off-tumor organ damage that has plagued some solid tumor CAR programs. The engineered cells were detectable in the patient’s peripheral blood for about a month after infusion, expanding as a polyclonal population, meaning that multiple distinct T cell clones carrying the receptor expanded in parallel rather than a single clone dominating. Polyclonal persistence is generally viewed favorably, as it suggests a robust, diverse immune response less vulnerable to outgrowth of tumor variants that could evade any single clone. The one-month persistence window is also consistent with a controlled, self-limited therapy, which may explain the clean toxicity profile even against a target like GPNMB that has low-level normal tissue expression.

The study did not stop at the celebration of a response, however. One lesion in the patient proved treatment-resistant, and the team subjected it to an advanced molecular interrogation known as spatial transcriptomics, a technique that maps which genes are active at precise locations within intact tissue. The analysis revealed that the resistant lesion harbored immunosuppressive niches, microanatomical pockets enriched for pathways and cell types that suppress T cell function, effectively creating local sanctuaries where the CAR T cells could not operate even when they reached the tumor. This finding transforms an apparent failure into a roadmap: resistance, in this case, was not about loss of the GPNMB target but about the tumor microenvironment building walls around the attacking cells.

That mechanistic insight pointed directly at a rational combination strategy. Immune checkpoint blockade, the class of drugs that includes antibodies against molecules such as PD-1 and its ligand PD-L1, works by releasing molecular brakes that tumors place on T cells. The researchers tested whether combining checkpoint blockade with GCAR1 would overcome the immunosuppressive niches, and in a xenograft model the combination produced synergy, with the two modalities together controlling tumors more effectively than either alone. For a translational program, this is a crucial result, because checkpoint inhibitors are already approved, widely available, and clinically familiar. A future trial testing GCAR1 alongside checkpoint blockade is an obvious and achievable next step, and the preclinical synergy data provide the justification.

The broader conceptual contribution of the study may ultimately matter more than any single clinical result. The MiT/TFE-family fusion proteins that drive ASPS and translocation renal cell carcinoma are master regulators, and the demonstration that their activity can be exploited through a surface readout like GPNMB establishes a general paradigm: oncogenic gene fusions, though intracellular and classically considered undruggable, can be converted into actionable surface targets by mapping the transcriptional programs they impose. The same strategy could in principle be extended to other fusion-driven cancers, a category that includes many pediatric sarcomas, leukemias, and carcinomas for which targeted drugs remain elusive. Rather than trying to inhibit an undruggable fusion protein directly, clinicians could train a patient’s immune system to recognize the distinctive surface signature that the fusion creates.

Challenges remain before GCAR1 or its successors become standard care. The clinical experience so far involves a single participant in an interim analysis, and larger cohorts will be needed to confirm response rates, define the optimal dosing, and fully characterize toxicities. The three-month duration of disease control, while encouraging, will need to extend into durable remissions, likely through combinations with checkpoint inhibitors or other microenvironment-modulating agents suggested by the spatial transcriptomics findings. Questions about whether resistance can emerge through GPNMB loss in other patients, and whether GPNMB expression levels in normal tissues vary enough between individuals to cause occasional toxicity, will require larger datasets. Nevertheless, the trajectory from target discovery through organoid and xenograft validation to a controlled, tolerated, clinically active infusion in a patient with one of oncology’s most feared sarcomas has been completed in a single study, a bench-to-bedside arc that few experimental therapies achieve so cleanly. For patients with ASPS, translocation renal cell carcinoma, and other fusion-driven solid tumors, the message is that the wall separating CAR T success in blood cancers from success in solid tumors is no longer impenetrable, and the first engineered cells are already through it.

Osteosarcoma represents a significant clinical challenge due to its aggressive nature and predilection for relapse or metastasis. Traditional treatment modalities such as chemotherapy and radiation have remained the mainstay but are accompanied by considerable toxicity and limited efficacy in advanced disease stages. Against this backdrop, immunotherapy, particularly chimeric antigen receptor T-cell (CAR-T) therapy, holds considerable promise. CAR-T therapy has revolutionized hematologic malignancies with remarkable remission rates in certain leukemia and lymphoma cases. However, its success in solid tumors like osteosarcoma has been impeded by the tumor microenvironment’s immunosuppressive characteristics that thwart effective immune cell infiltration and persistence.

Dr. Nowicki’s innovative research seeks to overcome these hurdles by engineering a next-generation “armed” CAR-T cell platform specifically targeting GD2, a disialoganglioside antigen abundantly and selectively expressed on osteosarcoma cells. These genetically modified T cells are equipped not only to recognize and eliminate tumor cells but also to secrete increased levels of tumor necrosis factor-alpha (TNF-alpha), a potent cytokine that modulates the immune landscape within the tumor microenvironment. The strategic secretion of TNF-alpha enhances the anti-tumor immune response by activating endogenous immune cells and disrupting the immune evasion mechanisms deployed by the tumor.

Key to the safety and efficacy of this approach is the tumor-specific release mechanism of TNF-alpha. Engineered CAR-T cells are programmed to secrete this cytokine exclusively upon engagement with GD2-positive osteosarcoma cells, thereby minimizing systemic toxicity often associated with cytokine therapies. This targeted delivery system provides a refined immunotherapeutic effect, enhancing tumor infiltration and cytotoxic potential while reducing collateral damage to healthy tissues.

Receiving the Hero Grant enables Nowicki and his team to expand their preclinical investigations, rigorously assessing both safety and efficacy in a variety of in vitro and in vivo osteosarcoma models. Comparative studies will juxtapose the novel TNF-alpha-armed GD2 CAR-T cells against conventional GD2 CAR-T cells to elucidate the added benefits conferred by localized cytokine secretion. These experiments include assessments of tumor growth inhibition, T-cell persistence, cytokine profiling, and immune cell recruitment within the tumor microenvironment.

Advanced molecular profiling technologies will play a pivotal role in this research phase, enabling the dissection of complex cellular interactions and signaling pathways influenced by the engineered therapy. Single-cell RNA sequencing, multiplex immunohistochemistry, and spatial transcriptomics are among the cutting-edge methodologies employed to unravel the dynamic interplay between CAR-T cells, tumor cells, and endogenous immune populations. Understanding these mechanisms is indispensable for optimizing therapeutic parameters and anticipating potential resistance or adverse effects.

The innovation represented by this CAR-T platform addresses a critical unmet need in oncology. Osteosarcoma patients with relapsed or metastatic disease face dismal prognoses, with five-year survival rates stagnating despite decades of clinical efforts. The integration of immunostimulatory mechanisms within cellular therapies promises a paradigm shift, potentially transforming osteosarcoma from a highly lethal tumor to a manageable or even curable entity.

Moreover, this approach aligns with the broader scientific objective of overcoming immune suppression in solid tumors, a hurdle that has limited the full potential of immunotherapies thus far. By engineering CAR-T cells that not only target cancer-associated antigens but concurrently modify the immunosuppressive milieu, the therapeutic index can be significantly improved. This dual functionality exemplifies the sophisticated bioengineering necessary for next-generation cancer therapies.

Dr. Nowicki’s work has gained recognition within the UCLA Health Jonsson Comprehensive Cancer Center and the UCLA Broad Stem Cell Research Center, underscoring the interdisciplinary collaboration fueling this research. With the crucial support from the MIB Agents’ Hero Grant, the team is poised to translate these preclinical successes into clinical trials, with the hopeful anticipation of inaugurating a new frontier in pediatric oncology.

Importantly, this research has implications beyond osteosarcoma. The modular design of the “armed” CAR-T platform could be adapted to other solid tumors expressing unique antigens and characterized by immunosuppressive microenvironments. This versatility offers hope for a wide range of refractory cancers that currently evade immunotherapeutic control.

In summary, the awarded funding will facilitate a comprehensive examination of the TNF-alpha-armed GD2 CAR-T cells’ potential to revolutionize osteosarcoma treatment. By combining precise tumor targeting with immune modulation, this innovative strategy aspires to surmount long-standing barriers in solid tumor immunotherapy and offer renewed hope to patients and families confronting this devastating disease.

Subject of Research: Next-generation CAR-T cell therapy for osteosarcoma featuring TNF-alpha-secreting GD2-targeted engineered T cells.

Article Title: Innovative TNF-alpha-Armed CAR-T Cells Offer New Hope Against Pediatric Osteosarcoma

News Publication Date: Not provided

Web References:
– https://www.uclahealth.org/providers/theodore-nowicki
– https://www.uclahealth.org/cancer

References: Not provided

Image Credits: Not provided

Keywords: Osteosarcoma, CAR-T cell therapy, Immunotherapy, Tumor microenvironment, GD2 antigen, TNF-alpha, Pediatric cancer, Solid tumor immunotherapy, Cellular engineering, Cancer immunology, Cancer research, Oncological treatments

One of the most compelling breakthroughs involves the engineering of CAR T cells to target uPAR, a surface protein intricately involved in tissue remodeling and wound healing. This protein’s persistent overexpression in tumor cells and supportive cells within the tumor microenvironment renders it an ideal immunotherapeutic target. Preclinical studies demonstrated that uPAR-directed CAR T cells effectively shrink solid tumors across lung, pancreatic, and ovarian cancer models in mice, even eliminating metastases in certain cases. This dual-action targeting disrupts not only the malignant cells but also the fibrotic and immunosuppressive stroma, a barrier that has notoriously hindered immunotherapy efficacy in solid tumors. Remarkably, these engineered cells spare normal immune counterparts, suggesting a promising therapeutic window and underscoring the potential expansion of CAR T therapies beyond hematologic malignancies.

MSK’s work transcends traditional tumor-centric views by framing cancer as a complex, interconnected ecosystem of malignant cells and their microenvironmental niches. The Marie-Josée and Henry R. Kravis Cancer Ecosystems Project, under the scientific guidance of Scott Lowe, PhD, epitomizes this approach. By unraveling the interactive cellular and molecular networks sustaining tumor growth, this initiative seeks to pioneer therapies that dismantle not only cancer cells but also their protective microenvironments. Such integrated strategies could revolutionize the management of historically intractable cancers.

Harnessing cutting-edge computational biology, Dana Pe’er, PhD, and colleagues unveiled how select cancer cell subtypes orchestrate their surroundings to establish a self-perpetuating tumor ecosystem. Utilizing spatial transcriptomics coupled with an innovative algorithm termed Wasserstein Wormhole, they delineated how ‘basal’ cancer cells attract myeloid immune populations that fortify the tumor’s defenses. Ablation of these basal cells in murine pancreatic cancer models resulted in ecosystem collapse, rendering tumors vulnerable to immune attack. These insights reveal that targeting cellular heterogeneity and intercellular communication within tumors can disarm the cocooning microenvironment that fosters therapeutic resistance.

Further computational dissection revealed highly plastic progenitor-like cancer cells in early pancreatic tumors that, when unchecked by tumor suppressor p53, fuel malignant progression through reprogramming their niche. This discovery clarifies the pivotal tumor-suppressive role of p53 in curbing cellular plasticity, offering new angles for therapeutic intervention aimed at reestablishing tissue homeostasis and thwarting early oncogenesis.

Immunomodulatory dynamics within tumors also received critical scrutiny, as Omar Abdel-Wahab, MD, presented pioneering research on the role of RNA splicing in mediating T cell exhaustion—a phenomenon that limits the efficacy of immunotherapies like checkpoint inhibitors. His team uncovered unique RNA splice variants in CD8+ T cells infiltrating melanoma, distinct from those in functional T cells. By manipulating RNA splicing pathways, they enhanced the anti-tumor capability of exhausted T cells, offering a molecular blueprint for reinvigorating immune responses and overcoming immune evasion in tumors.

The challenge of therapeutic resistance was starkly illuminated in the context of HER2-targeted antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd). Sarat Chandarlapaty, MD, PhD, alongside Joshua Drago, MD, MS, probed tumor biopsies from patients who relapsed following T-DXd treatment. Their analyses revealed two dominant resistance mechanisms: downregulation or loss of HER2 expression and mutational alterations that hinder ADC binding. Importantly, co-targeting HER2 and the alternative antigen TROP2 with combined ADC regimens achieved superior efficacy in preclinical models, suggesting a translational path towards overcoming resistance and refining targeted therapy paradigms.

In a novel exploration of tissue-level protection against cancer, Mara Sherman, PhD, focused on the pancreas’ mesenchymal stroma and its secretion of KITL, a signaling molecule crucial for maintaining tissue architecture and limiting cellular plasticity. Loss of KITL was observed during early stages of pancreatic tumorigenesis, facilitating cell state changes that promote malignancy. Sherman’s findings underscore the importance of stromal-tumor interactions and hint at preventive strategies that bolster tissue integrity to counteract cancer initiation.

Broader genomic investigations highlighted the influence of hereditary genetics beyond mere cancer susceptibility to encompass tumor evolution and mutational landscapes. Jian Carrot-Zhang, PhD, presented a compelling study demonstrating that inherited germline variants shape which somatic mutations tumors acquire. This multi-ancestral analysis unveiled population-specific genetic influences, emphasizing the necessity for personalized medicine approaches that account for genetic diversity and its impact on tumor biology and treatment responsiveness.

Another striking advance pertained to the body’s response to viral infections associated with cancer risk. Computational biologist Caleb Lareau, PhD, revealed how persistent Epstein-Barr virus (EBV) infection—implicated in autoimmune diseases and cancers—is modulated by host genetic variants identified through large-scale genomic and viral DNA data mining. By integrating data from hundreds of thousands of individuals, this research identified specific genetic loci linked to EBV persistence and related chronic diseases, opening avenues for targeted interventions aiming to mitigate virus-associated cancer risk.

Harmonizing these multifaceted discoveries, MSK’s research demonstrates unparalleled integration of molecular biology, computational science, immunology, and clinical insights. The collective efforts presented at AACR 2026 not only deepen our mechanistic understanding of cancer as a dynamic ecosystem but also propel the field toward innovative therapeutic strategies designed to disrupt tumor support networks, overcome resistance, and personalize treatment based on genetic and molecular cancer ecosystems.

In sum, the 2026 AACR Annual Meeting illuminated the future trajectory of oncology: a landscape where cutting-edge bioengineering, high-resolution spatial profiling, RNA biology, and germline-genome interactions converge to transform cancer diagnosis, prevention, and therapy. With these insights, MSK and collaborators are charting a bold course toward more effective and durable cancer treatments, fostering hope for patients facing some of the most formidable malignancies.

Subject of Research: Cancer Biology and Therapeutics, Tumor Microenvironment, Immuno-Oncology, Computational Oncology, Genetic Determinants of Cancer Progression, Resistance Mechanisms, Viral Oncology

Article Title: Emerging Paradigms in Cancer Ecosystems and Therapeutics: Insights from Memorial Sloan Kettering at AACR 2026

News Publication Date: 2026

Web References:

• https://www.aacr.org/meeting/aacr-annual-meeting-2026
• https://www.mskcc.org/news/treating-her2-amplified-early-stage-rectal-cancer-to-improve-quality-of-life
• https://www.mskcc.org/news/new-kras-targeted-therapy-shows-promise-against-pancreatic
• https://www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out

References:

• Cell (2026) on engineered uPAR-targeting CAR T cells and spatial transcriptomics studies
• Cancer Discovery (2026) on resistance mechanisms to HER2-targeted ADCs
• Nature (2025) on genetic determinants of Epstein-Barr virus persistence

Image Credits: Memorial Sloan Kettering Cancer Center

Keywords: Cancer Ecosystems, CAR T Cell Therapy, Tumor Microenvironment, RNA Splicing, Immunotherapy Resistance, HER2 Antibody-Drug Conjugates, Pancreatic Cancer, Genetic Variation, Epstein-Barr Virus, Computational Biology, Spatial Transcriptomics

Conventionally, CAR T therapy has demonstrated remarkable success in treating blood cancers such as leukemia and lymphoma by targeting specific, well-defined surface antigens like CD19 on malignant B cells. However, the extension of this approach to solid tumors has been thwarted by two critical hurdles: the lack of a consistently expressed surface antigen across tumor cells and the presence of a dense, immunosuppressive stroma composed of fibroblasts and myeloid cells that inhibit T cell infiltration and function. The new strategy presented by MSK researchers innovatively circumvents these barriers by targeting uPAR, a receptor highly expressed not only on malignant tumor cells but also on the supportive non-malignant cells within the tumor microenvironment.

uPAR is a cell surface receptor implicated in processes related to wound healing and tissue remodeling. In healthy tissues, its expression is limited primarily to myeloid immune cells; however, in the cancerous state, both tumor cells and the adjacent supportive niche cells abnormally upregulate uPAR. This upregulation signifies cellular states associated with malignancy, plasticity, fibrosis, and immunosuppression, thus marking uPAR as a pivotal molecule that orchestrates the tumor’s ecosystem. By leveraging this attribute, the MSK team designed CAR T cells that recognize and eradicate uPAR-positive cells, effectively dismantling the tumor itself and its protective microenvironment concurrently.

The preclinical evaluations, meticulously conducted through an array of cancer cell cultures, xenograft models harboring human tumors, and murine systems mimicking metastasis, demonstrated compelling evidence of the therapeutic potential of these uPAR-directed CAR T cells. Notably, in murine models of ovarian cancer, a notoriously therapy-resistant malignancy, these engineered T cells achieved the remarkable feat of eradicating metastatic lesions, eliciting sustained remission states. Furthermore, the persistence of these CAR T cells provided immunity against tumor rechallenge, highlighting the durability of the antitumor response.

The researchers also illuminated the utility of employing uPAR-targeted CAR T cells as adjunctive therapy post-surgical tumor debulking. In models where surgery alone rendered only temporary disease control, the administration of the CAR T cells significantly eliminated residual cancerous cells, proposing a paradigm shift in integrating cellular therapies with conventional surgical interventions to enhance long-term outcomes.

A profound insight into the molecular underpinnings of uPAR overexpression revealed a correlation with mutations in key oncogenes and tumor suppressors, including p53 and KRAS—mutations frequently encountered in aggressive and treatment-resistant cancers. This molecular association underscores the potential of uPAR-targeted therapy to address hard-to-treat cancers by attacking a common vulnerability linked to critical pathways driving malignancy and cellular plasticity.

Interestingly, the team capitalized on combining the uPAR CAR T cells with senescence-inducing chemotherapeutic agents such as cisplatin, which heighten uPAR expression on tumor cells, thereby enhancing the CAR T cells’ recognition and cytotoxicity. This combinatorial approach not only amplifies therapeutic efficacy but also exploits the dynamic changes within the tumor cell population induced by chemotherapy, addressing cancer’s notorious adaptability.

The innovation extends to molecular engineering sophistication: the designers selected uPAR binders that specifically target a form of the receptor less prone to being shed from the cell surface due to inflammatory signals. This specificity ensures sustained CAR T cell engagement, thereby optimizing the cytotoxic effect and circumventing a common mechanism by which tumors evade immune surveillance.

Crucially, this therapy’s dual-targeting capacity extends beyond malignant cells to encompass tumor-associated fibroblasts and immunosuppressive myeloid cells within the tumor microenvironment. This approach disrupts the cancer-supportive niche—a complex tissue landscape that enables tumor growth, immune evasion, and therapeutic resistance—introducing a multifaceted assault on the tumor ecosystem rather than a unidimensional attack on tumor cells alone.

The conceptual framework of this research is deeply rooted in viewing cancer through the lens of systems biology, recognizing tumors as dynamic ecosystems constituted by cancer cells and their intricate interactions with surrounding stroma and immune cells. Such an ecosystem-centered outlook empowers the development of interventions aimed at perturbing these critical intercellular networks, exemplified by the uPAR-targeted CAR T cells. This strategy reflects the paradigm of the Marie-Josée and Henry R. Kravis Cancer Ecosystems Project at MSK, which promotes innovative therapies by dissecting and targeting these interconnected cellular systems.

Beyond its applications in oncology, the therapeutic implications of targeting uPAR-positive cells extend to various fibrotic, inflammatory, and degenerative diseases wherein similar pathological cell types contribute to disease progression. Therefore, therapies built upon this foundation promise broader biomedical applications, opening new frontiers in treating diseases characterized by aberrant tissue remodeling and inflammation.

Monitoring the disease burden and therapeutic efficacy also benefits from the identification of uPAR-related biomarkers. The team demonstrated the potential of measuring soluble uPAR (suPAR) fragments in the bloodstream and utilizing uPAR-targeted positron emission tomography (PET) imaging to non-invasively visualize tumor presence and treatment response, which could revolutionize real-time disease surveillance and personalized medicine approaches.

The discovery and development of uPAR-targeted CAR T cells signify not only a technical tour de force in immunoengineering but also a conceptual leap in treating solid tumors by simultaneously targeting both the cancer cells and their supportive milieu. As this therapy progresses toward clinical evaluation, it heralds a potentially transformative advancement in cancer treatment modalities, offering hope for overcoming long-standing obstacles in solid tumor immunotherapy.

Subject of Research:
Article Title: A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
News Publication Date: 30-Mar-2026
Web References: https://www.cell.com/cell/fulltext/S0092-8674(26)00269-2, https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/immunotherapy/car-cell-therapy
References: DOI: 10.1016/j.cell.2026.03.002
Image Credits: Memorial Sloan Kettering Cancer Center

Keywords: CAR T cell therapy, uPAR, tumor microenvironment, solid tumors, immunotherapy, cancer biology, cellular senescence, tumor ecosystem, metastatic cancer, molecular oncology, immunoengineering, targeted therapy

The tumor microenvironment (TME) represents a formidable obstacle for immune-based therapies, as it enables tumor cells to evade immune surveillance through multiple pathways, including the secretion of immunosuppressive molecules like VEGF. VEGF plays a multifaceted role by stimulating aberrant blood vessel formation, facilitating tumor survival in hypoxic conditions, and creating a physical and chemical fortress that restricts immune cell infiltration and function. Traditional therapeutic strategies that systemically inhibit VEGF, such as the monoclonal antibody bevacizumab, suffer from limited efficacy and systemic toxicities, which have constrained their clinical success.

The UCLA research team has circumvented these limitations by genetically engineering CAR-T cells to secrete a specialized single-chain variable fragment (scFv) antibody that neutralizes VEGF locally within the tumor microenvironment. This fusion of direct tumor killing and simultaneous VEGF blockade heralds a transformative advancement in CAR-T technology, effectively “arming” the T cells with dual functionality. By producing VEGF blockers at the tumor site, these armored CAR-T cells circumvent the need for systemic drug administration, potentially minimizing the off-target effects and maximizing therapeutic potency exactly where it is most required.

Preclinical testing conducted in rigorous mouse models of glioblastoma and ovarian cancer demonstrated striking therapeutic benefits of the armored CAR-T cells compared to conventional CAR-T therapy and systemic VEGF inhibition. In ovarian cancer models, the engineered cells not only decelerated tumor progression but enhanced survival rates and boosted the production of interferon-gamma, a cytokine critical for triggering robust immune responses against malignancy. The efficacy was further exemplified in highly aggressive glioma mouse models, where the armored CAR-T completely eradicated tumors in a majority of subjects, whereas traditional CAR-T cells achieved significantly lower complete response rates.

Intriguingly, the study revealed that standard CAR-T therapy paradoxically exacerbated adverse tumor features by promoting abnormal neovascularization and increasing tumor hypoxia, which could undermine immune cell function. The armored CAR-T cells, conversely, normalized the tumor vasculature, alleviating oxygen deprivation and creating a more favorable terrain for immune-mediated tumor eradication. This normalization effect likely contributes considerably to the observed enhanced functionality and energetic state of the engineered CAR-T cells, as well as to the recruitment and activation of endogenous immune populations.

The therapeutic innovation centers on the concept that the immunosuppressive tumor microenvironment is modifiable and can be “re-educated” rather than only targeted for destruction. By locally delivering VEGF inhibition through CAR-T cells themselves, the therapy realigns the tumor milieu from hostile to permissive, enabling both the engineered and native immune cells to perform their anti-cancer functions more effectively. This dual modality not only intensifies the CAR-T cell cytotoxicity but also promotes a systemic anti-tumor immune response, offering a potentially durable and comprehensive therapeutic benefit.

While VEGF blockade is not new to cancer treatment, this approach using CAR-T cells as living drug factories represents a paradigm shift, leveraging genetic engineering to overcome the chronic challenges faced by conventional immunotherapies in solid tumors. This strategy also avoids the logistical and pharmacokinetic hurdles of repeated systemic drug administration, instead harnessing the CAR-T cells’ ability to proliferate and sustain VEGF inhibition dynamically in situ, adapting to tumor growth and heterogeneity.

The implications of this research are vast, given the historical difficulty in treating malignancies like glioblastoma and ovarian cancer—tumor types notorious for their aggressiveness, recurrence, and resistance to standard therapies. The armored CAR-T cells’ capacity to induce complete remission in preclinical glioma models underscores the potential to redefine therapeutic outcomes for patients facing these deadly cancers, which currently have very limited effective treatment options.

Led by Yvonne Chen, PhD, co-director of the Tumor Immunology and Immunotherapy Program at UCLA’s Jonsson Comprehensive Cancer Center, this study sets the stage for next-generation immunotherapy designs that integrate tumor microenvironment modification with targeted immunoassault. Chen emphasizes that by reshaping the hostile microenvironment, this approach does not merely attack tumor cells but also enlists the body’s own immune system to join the battle, which may lead to sustained long-term remission.

The partnership with Dr. Han-Chung Wu’s team at Academia Sinica in Taiwan facilitated the creation of the novel VEGF-targeting scFv, a crucial element allowing the CAR-T cells to maintain focused VEGF blockade. This international collaboration exemplifies the increasingly interdisciplinary nature of modern biomedical innovation, combining advances in molecular engineering, immunology, and cancer biology.

Ongoing refinements and future clinical development will determine how this technology translates to the human oncology landscape, but the preclinical data provide a robust proof-of-concept that armored CAR-T cells could redefine therapy for solid tumors. Their ability to counteract VEGF-mediated suppression and hypoxia-induced resistance mechanisms marks a meaningful advance in overcoming the entrenched immunotherapy barriers posed by solid malignancies.

This pioneering research heralds a new frontier in cancer immunotherapy where multifunctional, self-sustaining CAR-T cells can penetrate and dismantle the protective tumor microenvironment whilst orchestrating an amplified anti-cancer immune response throughout the body. If successful in clinical trials, this approach could significantly broaden the applicability and effectiveness of CAR-T therapies beyond hematologic cancers and open new avenues for treating some of the most lethal solid tumors faced by patients worldwide.

Subject of Research: Next-generation CAR-T cell therapy targeting VEGF to neutralize the tumor microenvironment in solid cancers

Article Title: Not provided

News Publication Date: Not provided

Web References: Not provided

References: Not provided

Image Credits: Not provided

Keywords: CAR-T therapy, tumor microenvironment, VEGF blockade, immune suppression, solid tumors, glioblastoma, ovarian cancer, immunotherapy, single-chain variable fragment (scFv), tumor vasculature, hypoxia, oncology

At the core of this novel approach lies the problem of antigen diversity within solid tumors. Unlike blood cancers, where malignant cells often express uniform surface proteins such as CD19, making them easily identifiable by CAR T cells, solid tumor cells exhibit a vast array of molecular profiles. This heterogeneity disrupts the efficacy of therapies designed to target a single antigen, as subsets of tumor cells may evade detection and survive treatment. Classical CAR T cells are effective only when the target antigen is sufficiently abundant to trigger activation, meaning low-level antigen expression can result in tumor persistence and relapse. The inability to detect and destroy the last vestiges of cancer cells within solid tumor masses has, until now, represented a formidable barrier to curative immunotherapy.

The breakthrough led by the team at CICET focuses on a molecular marker known as CD70. Although previous research characterized CD70 expression in solid tumors as inconsistent and patchy—leading to its dismissal as a reliable target—Sophie Hanina, a research associate scientist and lead author of the study, hypothesized that current detection techniques lacked the sensitivity to identify low-level expression of this antigen. Through the development and implementation of innovative detection methods, the team revealed that every cancer cell in multiple solid tumor types, including pancreatic, kidney, and ovarian cancers, carries at least trace amounts of CD70 on its surface. This nuanced understanding reframes CD70 as a universal homing beacon within these malignancies, opening the door for targeted immunotherapy with unprecedented precision.

To harness this finding therapeutically, Hanina and colleagues utilized HIT cells, a specialized offshoot of CAR T cells endowed with a distinctive ability: the exquisite sensitivity of natural T cells to minimal antigen presence. Unlike traditional CAR T cells, whose activity thresholds preclude engagement with cells expressing minute quantities of the target antigen, HIT cells can recognize and respond to these subtle molecular signatures. This capability allows HIT cells to surveil the tumor microenvironment with acute vigilance, identifying and attacking even the sparsest tumor cells that would otherwise escape detection.

Experimental data from preclinical models offer compelling evidence of HIT cells’ superior efficacy. In murine models bearing pancreatic, kidney, and ovarian tumors, CD70-directed HIT cells achieved complete eradication of malignancies, a feat traditional CD70 CAR T cells could not replicate. While conventional CAR T cells demonstrated only partial tumor control, HIT cells eliminated the disease entirely without detectable damage to healthy tissues, owing to the restricted expression of CD70 in non-cancerous cells. This selective cytotoxicity highlights the therapeutic potential for HIT cell therapy in solid tumors, promising both enhanced effectiveness and reduced off-target toxicity.

Crucial to the success of HIT therapies is their retention of natural immune cell signaling pathways, which enable a more physiologically relevant response to antigen exposure. By integrating these pathways within a chimeric antigen receptor framework, HIT cells combine engineering precision with biologically optimized sensitivity. This fusion allows for a calibrated immune attack on cancer cells expressing even vanishingly small antigen amounts. The implications for solid tumor immunotherapy are profound, as HIT cells could address the persistent problem of antigen escape—a major factor in treatment failure.

Despite these promising preclinical results, solid tumors impose additional layers of complexity that HIT cell therapy must overcome. The tumor microenvironment often suppresses immune function through immunosuppressive cytokines, regulatory cells, and physical barriers such as dense extracellular matrices. While CD70-targeting HIT cells solve the critical hurdle of tumor cell identification, ongoing research aims to enhance their trafficking, persistence, and resilience within hostile tumor niches. Combining HIT cell therapy with agents that modulate the tumor microenvironment may further amplify therapeutic outcomes and pave the way for durable remissions.

Looking ahead, clinical trials are in preparation at Columbia University Irving Medical Center to evaluate the safety and efficacy of CD70 HIT cells in patients with ovarian and other solid cancers. The breadth of CD70 expression across diverse tumor types—including glioblastoma and pancreatic adenocarcinoma—suggests that this therapy could have broad applicability. If successful in humans, HIT cell therapy could redefine the landscape of cancer treatment, offering hope for complete remission in cancers that have long evaded curative interventions.

The development of HIT cells signifies a pivotal advancement in cellular immunotherapy, encapsulating years of expertise in T cell engineering and immunobiology. Spearheaded by Michel Sadelain, a trailblazer in CAR T cell therapy, this innovation addresses one of the most critical obstacles in oncology: the need to detect and eliminate every malignant cell. The insights gained from CD70 expression patterns and the functional testing of HIT cells provide a blueprint for developing more sensitive and precise immunotherapies against a wider spectrum of solid tumors.

Moreover, the study underscores the importance of refining molecular detection tools in oncology. By revealing the overlooked presence of CD70 at low levels, the research challenges assumptions about tumor antigenicity and encourages re-examination of other molecular targets that may have been prematurely abandoned. Such methodological advancements have the potential to uncover new therapeutic opportunities and enhance personalized treatment strategies.

In conclusion, the emergence of HIT cell therapy as a next-generation cancer immunotherapy offers an innovative solution to the enduring challenge posed by solid tumors. Through enhanced sensitivity to low-density antigens like CD70, HIT cells demonstrate the ability to comprehensively target heterogeneous tumor cell populations, achieving complete tumor eradication in preclinical models. The forthcoming clinical investigations will be pivotal in translating these findings into transformative cancer treatments, potentially improving survival and quality of life for patients afflicted with some of the most intractable cancers.

Subject of Research: The study focuses on cellular immunotherapy targeting CD70 expression in solid tumors using highly sensitive HIT (Highly-Incucated T cell) technology to improve detection and eradication of heterogeneous cancer cell populations.

Article Title: Sensitive CAR T cells redefine targetable CD70 expression in solid tumors

News Publication Date: February 26, 2026

Web References: http://dx.doi.org/10.1126/science.adv7378

Keywords: Cancer treatments, Cell therapies, Chimeric antigen receptor therapy

Recent groundbreaking research has introduced a novel approach to conquering these inherent challenges in solid tumor immunotherapy. Scientists have engineered a new generation of ultra-sensitive CAR T cells designed to detect exceedingly low levels of the tumor-associated antigen CD70, a protein that is aberrantly overexpressed across a range of solid tumors but exhibits pronounced heterogeneity in its expression pattern among different tumor cells. This heterogeneity has historically limited the effectiveness of CAR T cells, as conventional receptors fail to recognize tumor cells expressing CD70 beneath the detection threshold.

Building on intricate patient-derived xenograft models that recapitulate the uneven CD70 distribution observed in kidney cancer patients, the research team led by Sophie Hanina uncovered a spectrum of CD70 expression within tumors. Intriguingly, even cells categorized as CD70-negative harbored low but significant amounts of this antigen, insufficient to trigger elimination by existing CAR T modalities. This nuanced understanding of antigen distribution underscored the necessity for enhanced receptor sensitivity to broaden the therapeutic window against solid tumors.

The innovation came with the development of a highly selective and sensitive CAR construct termed the HLA-independent T cell (HIT) receptor. This advanced chimeric receptor transcends the limitations of conventional CARs by detecting minimal antigenic presence, enabling immune cells to target and eradicate tumor populations with diverse CD70 expression confidently. Preclinical models using mice and cultured cells demonstrated that CD70-HIT T cells achieved complete and sustained tumor clearance across renal, ovarian, and pancreatic cancer models, despite the patchy antigen expression characteristic of these malignancies.

This remarkable efficacy repositions CD70 as a prime pan-cancer target, opening new avenues for treating an array of solid tumors previously thought refractory to CAR T cell intervention. The authors propose the HIT receptor design as a blueprint for identifying additional “stealth” tumor antigens—those expressed at levels traditionally considered subthreshold for immunotherapeutic targeting—thereby expanding the horizon for precision-engineered cancer treatments.

At the molecular level, the HIT receptor’s enhanced sensitivity stems from refined antigen-binding kinetics and signal transduction efficiency, allowing T cells to be activated by a fractional antigen presence without compromising specificity. Such design ingenuity mitigates the risk of off-tumor toxicity, a significant concern when targeting antigens with low differential expression between cancerous and healthy tissues.

Importantly, this research aligns with a growing recognition that tumor heterogeneity is a formidable barrier to uniform cancer eradication. The capacity to detect and respond to low-density antigens provides a strategic advantage in outmaneuvering tumor escape mechanisms, which often exploit antigen loss or modulation to evade immune surveillance. By forcing the immune system’s hand through highly sensitive recognition, HIT CAR T cells reduce the likelihood of resistant tumor clones emerging.

The translational potential of this work is profound. Given the prevalence of CD70 expression across more than twenty solid tumor types, as documented in the study, CD70-targeted HIT CAR T therapy could form a backbone for multifaceted treatment regimens. These therapies might be integrated with checkpoint inhibitors, chemotherapy, or radiotherapy to orchestrate comprehensive tumor destruction.

From a clinical development standpoint, the HIT CAR T cell platform invites a reevaluation of antigen thresholds considered viable for targeting, suggesting that the therapeutic index can be expanded through receptor engineering rather than antigen discovery alone. Future investigations will undoubtedly focus on the safety profile of HIT CAR T cells in patient trials, durability of responses, and potential mechanisms underlying observed tumor eradication.

Moreover, this innovative approach fosters renewed optimism in addressing tumor antigen heterogeneity systematically. By harnessing receptor sensitivity as a modifiable parameter, immunotherapies can be tailored not only to canonical tumor antigens but also to those previously dismissed due to expression variability or low abundance.

In conclusion, the advent of CD70-HIT CAR T cells signifies a critical stride toward overcoming the intrinsic challenges of solid tumor immunotherapy. This strategy exemplifies how deep molecular characterization of tumor antigen landscapes combined with cutting-edge receptor design can redefine boundaries for immune targeting, potentially offering lasting remissions where few effective options previously existed.

As the oncology research community eagerly anticipates clinical validation, the current findings provide a compelling proof-of-concept that sensitive CAR engineering could reshape cancer treatment paradigms, transforming solid tumor immunotherapy from a promising idea into a clinical reality.

Subject of Research: Development of ultra-sensitive CAR T cells targeting heterogeneous CD70 expression in solid tumors.

Article Title: Sensitive CAR T cells redefine targetable CD70 expression in solid tumors

News Publication Date: 26-Feb-2026

Web References: 10.1126/science.adv7378

Keywords

CAR T cells, solid tumors, CD70, immunotherapy, tumor heterogeneity, HIT receptor, patient-derived xenograft, kidney cancer, ovarian cancer, pancreatic cancer, tumor antigen sensitivity, chimeric antigen receptor.

The use of CAR-T cell therapy has revolutionized the treatment of hematological malignancies, yet its application in solid tumors remains limited. The inherent complexity of solid tumors, characterized by dense cellular structures, immunosuppressive factors, and altered metabolism, presents a significant barrier to the infiltration and functionality of CAR-T cells. By employing outer membrane vesicles derived from engineered bacteria, the researchers have found a promising solution to these formidable challenges.

The engineered OMVs serve as a unique delivery system, capable of encapsulating and transporting therapeutic agents directly to the tumor site. This targeted approach allows for a dual action: not only do the OMVs enhance the localization of CAR-T cells to the tumor microenvironment, but they also modulate the immune landscape surrounding the tumor. This modulation is crucial, as solid tumors often deploy multiple mechanisms to evade immune detection and destruction.

One of the most remarkable aspects of the research is the ability of the engineered OMVs to deliver immune-stimulatory signals directly to the tumor site. This delivery is essential for reactivating exhausted T cells and rallying a robust immune response against the tumor. The team demonstrated that these vesicles could facilitate the presentation of tumor antigens in a manner that significantly increased T cell activation and proliferation. Consequently, the combination of CAR-T cell therapy with OMVs resulted in a synergistic effect, leading to enhanced tumor regression in preclinical models.

Moreover, the study reveals that the incorporation of OMVs not only amplifies the efficacy of CAR-T cells but also improves their persistence within the tumor environment. This is a crucial factor, as the sustained presence of CAR-T cells is often necessary to achieve long-term remission in patients with solid tumors. Through manipulation of the OMV composition, the researchers were able to influence the pharmacokinetics and biodistribution of CAR-T cells, effectively keeping them engaged in the fight against the tumor for extended periods.

In their experiments, Li et al. utilized various preclinical tumor models that closely mimic human cancers to evaluate the performance of their engineered OMVs alongside CAR-T cell therapy. The results were striking: Mice treated with the combined therapy showed statistically significant improvements in tumor size reduction compared to those receiving CAR-T cells alone. Additionally, the overall survival rates in the combination therapy cohorts were markedly higher, indicating a promising avenue for increasing the success rates of CAR-T therapies in solid tumors.

The implications of this research extend beyond scientific curiosity; it represents a paradigm shift in our approach to cancer therapy. By integrating cutting-edge biotechnological approaches with established immunotherapeutic techniques, the study advocates for a multifaceted treatment regimen that leverages the strengths of both methodologies. This interdisciplinary strategy could pave the way for clinical trials that may soon bring these advancements from the laboratory to the bedside, offering hope to countless patients who have exhausted conventional therapies.

Furthermore, the safety profile of the engineered OMVs appears promising, with minimal adverse effects observed during the study. This is a critical consideration, as the safety of novel therapeutic approaches is paramount, especially when considering the vulnerable patient population typically associated with advanced solid tumors. The authors highlight the need for continued investigation into the long-term effects of OMV application and the potential for unexpected immunological responses.

As the landscape of cancer treatment continues to evolve, the integration of engineered outer membrane vesicles into CAR-T cell therapy holds the potential to redefine the boundaries of what is achievable in oncology. The convergence of these two powerful modalities could not only enhance the effectiveness of treatments but also transform the standard of care for solid tumors that have previously resisted even the most advanced therapeutic strategies.

The feasibility of scaling up the production of engineered OMVs also presents exciting possibilities for their application in clinical settings. Future investigations will need to focus on optimizing the manufacturing processes, ensuring consistency, and complying with regulatory requirements. If successful, this breakthrough could lead to a new era of personalized medicine where therapies are tailored to the unique characteristics of each patient’s tumor, maximizing treatment efficacy while minimizing risks.

In summary, the research led by Li et al. represents a significant advancement in the ongoing battle against solid tumors. The innovative use of engineered outer membrane vesicles alongside CAR-T cell therapy not only addresses the logistical challenges of tumor targeting but also reinvigorates the immune response against cancer. As more studies are conducted and the clinical potential of this technique is explored, the future looks promising for patients facing the daunting challenge of solid tumors.

By leveraging the power of biotechnology and immunotherapy, this research provides a beacon of hope, igniting the imagination and ambition of the scientific community as they strive to uncover novel treatment avenues for one of humanity’s most formidable adversaries. The journey from bench to bedside may be fraught with challenges, but the outcomes of these pioneering efforts could ultimately rewrite the narrative of solid tumor treatment in the years to come.

Subject of Research: Engineered Outer Membrane Vesicles to Enhance CAR-T Cell Therapy for Solid Tumors

Article Title: Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy.

Article References:

Li, X., Li, X., Shi, J. et al. Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy.
Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-025-01575-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-025-01575-6

Keywords: CAR-T cell therapy, engineered outer membrane vesicles, solid tumors, immune response, cancer treatment, tumor microenvironment.